Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada

被引：0
|
作者：
Peixoto, Renata D'Alpino [1 ]
Renouf, Daniel John [1 ]
Gill, Sharlene [1 ]
Cheung, Winson Y. [1 ]
Kennecke, Hagen F. [1 ]
Lim, Howard John [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [32] Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC)
    Qin, Shukui
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Li, Cindy
    Chen, Wenfeng
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Impact of gender on survival of patients (pts) with hepatocellular carcinoma (HCC): A SEER analysis
    Yang, Dongyun
    Usher, Josh
    LoCoco, Jordan
    Pritesh, Chaudhari
    Lenz, Heinz-Josef
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met plus hepatocellular carcinoma (HCC) previously treated with sorafenib
    Decaens, T.
    Barone, C.
    Assenat, E.
    Wermke, M.
    Fasolo, A.
    Merle, P.
    Blanc, J-F.
    Grando, V.
    Bruns, R.
    Straub, J.
    Zhao, C.
    Faivre, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 48 - 48
  • [35] Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Harding, James J.
    Kelley, Robin Kate
    Tan, Benjamin R.
    Iobst, Emily
    Boussayoud, Chayma
    Muenkel, Kerri E.
    Do, Richard K. G.
    Chou, Joanne F.
    Capanu, Marinela
    Ruiz, Carmen
    Lee, Mariam Rodriguez
    Wilton, John
    Iyer, Renuka V.
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Phase II trial of tepotinib vs sorafenib for treatment-naive advanced hepatocellular carcinoma (HCC) in Asian patients
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Pazo Cid, R. A.
    Esquerdo, G.
    Puertolas, T.
    Calderero, V.
    Gil, I.
    Lao, J.
    Millastre, E.
    Alvarez-Alejandro, M.
    Madani, J.
    Anton, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).
    El Dika, Imane H.
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Germino, Joseph
    O'Reilly, Eileen Mary
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
    Kudo, Masatoshi
    Finn, Richard S.
    Meyer, Tim
    Boisserie, Frederic
    Li, Songzi
    Chen, Yaxi
    Abdrashitov, Ramil
    Zhu, Andrew X.
    Vogel, Arndt
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] The Decrease of Blood Flow After Administration of Sorafenib May Improve Overall Survival in Patients With Advanced Hepatocellular Carcinoma
    Arizumi, Tadaaki
    Ueshima, Kazuomi
    Kudo, Masatoshi
    GASTROENTEROLOGY, 2012, 142 (05) : S979 - S979
12345